Effects of stringent criteria on eligibility for clozapine among public mental health clients.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Psychiatric Services

• Publication date

  1995-08-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1176/PS.46.8.801PMID 7583481
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clozapine pharmacology and tardive dyskinesia

  2004cited by this paper
• A retrospective study on the long-term efficacy of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year period

  2004cited by this paper
• Psychopharmacology and the Ethics of Resource Allocation

  1993cited by this paper
• Oedipus at Delphi

  1993cited by this paper
• Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.

  1993cited by this paper
• Assessment of Costs and Benefits of Drug Therapy for Treatment-Resistant Schizophrenia in the United Kingdom

  1993cited by this paper
• Clozapine use by state programs: public mental health systems respond to a new medication.

  1993cited by this paper
• Treatment of the neuroleptic-nonresponsive schizophrenic patient.

  1992cited by this paper
• Hospitalization Rates Among Clozapine-Treated Patients: A Prospective Cost-Benefit Analysis

  1992cited by this paper
• Treatment programme and long‐term outcome in chronic schizophrenia

  1990cited by this paper
• Guidelines for the dosage of antipsychotic drugs

  1990cited by this paper
• Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients.

  1990cited by this paper
• Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

  1990cited by this paper
• Care of persons with schizophrenia: a statistical profile.

  1989cited by this paper
• The current status of neuroleptic therapy.

  1989cited by this paper
• Clozapine: an atypical antipsychotic agent.

  1989cited by this paper
• Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

  1988cited by this paper
• Treatment of schizoaffective disorders.

  1984cited by this paper
• ON THE METHODS AND THEORY OF RELIABILITY

  1976cited by this paper

• Aberrant connectivity in the hippocampus, bilateral insula and temporal poles precedes treatment resistance in first-episode psychosis: a prospective resting-state functional magnetic resonance imaging study with connectivity concordance mapping

  2024cites this paper
• Real-World Treatment of Schizophrenia in Adults With a 22q11.2 Microdeletion: Traitement dans le monde réel de la schizophrénie chez des adultes atteints du syndrome de microdélétion 22q11.2

  2024cites this paper
• Safety of BEN guidelines in clozapine treatment: A Canadian perspective.

  2024cites this paper
• Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates

  2023influential citation
• Efficacy and safety of maintenance electroconvulsive therapy (M-ECT) in treatment-resistant schizophrenia: A case series.

  2022cites this paper
• Elevated salivary kynurenic acid levels related to enlarged choroid plexus and severity of clinical phenotypes in treatment-resistant schizophrenia.

  2022cites this paper
• Treatment-resistant schizophrenia: How far have we traveled?

  2022cites this paper
• Striatal glutamate, subcortical structure and clinical response to first-line treatment in first-episode psychosis patients.

  2021cites this paper
• Das ZI-Track-Konzept in der Behandlung psychotischer Störungen

  2019cites this paper
• Prevalence of treatment-resistant psychoses in the community: A naturalistic study

  2019influential citation
• Das ZI-Track-Konzept in der Behandlung psychotischer Störungen

  2019cites this paper
• Confused Connections? Targeting White Matter to Address Treatment Resistant Schizophrenia

  2018cites this paper
• Prescription and Underprescription of Clozapine in Dutch Ambulatory Care

  2018cites this paper
• Identifying improvable employment-related factors in schizophrenia patients.

  2018cites this paper
• Neuromorphic computational models for machine learning and pattern recognition from multi-modal time-series data

  2018cites this paper
• First-episode psychosis in treatment-resistant schizophrenia: a cross-sectional study of a long-term follow-up cohort

  2018cites this paper
• Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy

  2017cites this paper
• m-RESIST, a complete m-Health solution for patients with treatmentresistant schizophrenia: a qualitative study of user needs and acceptability in the Barcelona metropolitan area.

  2017cites this paper
• International trends in clozapine use: a study in 17 countries

  2017cites this paper
• Brain dysconnectivity as a biomarker of treatment resistance in schizophrenia

  2017cites this paper
• Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice

  2017cites this paper
• Efficacité et tolérance de la clozapine sur les comportements-défis des patients adultes présentant un trouble du spectre de l’autisme

  2017cites this paper
• Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review

  2017cites this paper
• Effectiveness of Electroconvulsive Therapy Augmentation on Clozapine-Resistant Schizophrenia

  2016cites this paper
• An innovative and integrative m-Health solution for treatment resistant schizophrenia patients

  2016cites this paper
• Measuring Users’ Receptivity Toward an Integral Intervention Model Based on mHealth Solutions for Patients With Treatment-Resistant Schizophrenia (m-RESIST): A Qualitative Study

  2016cites this paper
• Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up

  2016cites this paper
• Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: An analysis of multi-factors predicting long-term prognosis.

  2016cites this paper
• Clozapina: una revisión

  2016cites this paper
• Motivational Deficits in Schizophrenia

  2016cites this paper
• Practitioner attitudes to clozapine initiation

  2014cites this paper
• L'association clozapine avec un autre antipsychotique dans le traitement de la schizophrénie hyper-résistante : analyse des pratiques de prescription au travers d'une étude observationnelle

  2014cites this paper
• Clozapine augmented with amisulpride in 3 cases of treatment-resistant early- and very early-onset schizophrenia.

  2013cites this paper
• Tranylcypromine discontinuation symptoms and withdrawal delirium.

  2013cites this paper
• Treatment-Resistant Schizophrenia: Prevalence and Risk Factors

  2013cites this paper
• Evolution of the Concept of Treatment-resistant Schizophrenia: Toward a Reformulation for Lack of an Adequate Response

  2012cites this paper
• The evolving concept of Treatment- Resistant Schizophrenia.

  2011cites this paper
• Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology

  2011cites this paper
• Development and evaluation of a standardised pathway for clozapine use in treatment resistant schizophrenia in institutionalised patients

  2011cites this paper
• Evaluation and medication therapy for treatment resistance in schizophrenia

  2009cites this paper
• Clozapina: una visión histórica y papel actual en la esquizofrenia resistente al tratamiento

  2008cites this paper
• Differential pharmacological regulation of drug efflux and pharmacoresistant schizophrenia

  2008cites this paper
• Clozapina: una visión histórica y papel actual en la esquizofrenia resistente al tratamiento Clozapine: an historical view and current use in treatment resistant schizophrenia

  2008cites this paper
• Management issuesTreatment resistance in schizophrenia

  2008cites this paper
• Quid des schizophrénies résistantes

  2008cites this paper
• Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment

  2007cites this paper
• PHARMACOGENETIQUE DE LA SCHIZOPHRENIE

  2007cites this paper
• Dealing with treatment resistance to clozapine : characteristics of treatment response in schizophrenia

  2006cites this paper
• [Pharmacological treatment resistant schizophrenia].

  2006cites this paper
• Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein

  2006influential citation
• Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge

  2006cites this paper
• A Case Study: Treatment of Refractory Schizoaffective Disorder with Aripiprazole

  2005cites this paper
• Treatment resistance in schizophrenia

  2005cites this paper
• Management of clozapine-resistant schizophrenia

  2005cites this paper
• [Atypical antipsychotics in therapy refractory schizophrenia].

  2004cites this paper
• Atypische Antipsychotika bei therapieresistenter Schizophrenie

  2004cites this paper
• Concept and Management of Treatment Resistant Schizophrenia (TRS)

  2004cites this paper
• Évaluation de la notion de « schizophrénie résistante ». Aspects pharmacologiques et incidences des nouveaux antipsychotiques

  2004cites this paper
• Efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: a prospective open trial.

  2003cites this paper
• Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia.

  2002cites this paper
• Efficacy of Electroconvulsive Therapy Combined with Antipsychotic Medication in Treatment-Resistant Schizophrenia: A Prospective, Open Trial

  2002cites this paper
• A patient with treatment‐resistant schizophrenia and cytochrome P4502D6 gene duplication

  2002cites this paper
• Management of treatment resistance in schizophrenia.

  2001cites this paper
• Esquizofrenia "resistente". Conceptos confusos y tratamientos esperanzadores

  2001cites this paper
• Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison.

  2001cites this paper
• Treatment costs and patient outcomes with use of risperidone in a public mental health setting.

  1999cites this paper
• Der Einsatz atypischer Neuroleptika bei therapieresistenten schizophrenen Psychosen

  1999cites this paper
• Modeling of annual treatment costs and health outcomes of antipsychotic agents for schizophrenic populations. Based on a presentation by Josephine Mauskopf, PhD.

  1999cites this paper
• Annual health outcomes and treatment costs for schizophrenia populations.

  1999cites this paper
• Treatment-resistant schizophrenia--the role of clozapine.

  1997cites this paper
• Evaluation of treatment-resistant schizophrenia.

  1997cites this paper
• Factors which can make Patients Difficult to Treat

  1996cites this paper
• Pharmacoeconomics of antipsychotic drug therapy.

  1996cites this paper
• Clozapine eligibility among state hospital patients.

  1996cites this paper
• Clozapine eligibility: the effect of stringent criteria on ethnic, gender and age subgroups of schizophrenic patients.

  1996cites this paper